Recruiting studies: Low Grade Serous Ovarian Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · 106 location(s) · Verastem, Inc. · NCT06072781 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978 Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2 · 12 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05872204 Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700 Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00488878 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ova
Phase 1/Phase 2 · 52 location(s) · Regeneron Pharmaceuticals · NCT03564340 Study of NTB-928 in R/R OC
Phase 1 · 2 location(s) · TeneoSeven, Inc. · NCT07690189 Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Phase 2 · 1 location(s) · Sarah K. Lynam MD · NCT05113368 A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06394804 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.